🧬 Khorana Score (Chemotherapy VTE Risk)
Predict chemotherapy-associated VTE risk in ambulatory cancer patients (Khorana score).
Clinical takeaway
Score ≥ 2 may prompt prophylaxis (apixaban/rivaroxaban/LMWH).
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Decide on outpatient thromboprophylaxis during chemotherapy.
How it works
Cancer site (2/1/0) + platelets ≥ 350 (1) + Hb < 10/ESA (1) + WBC > 11 (1) + BMI ≥ 35 (1). ≥ 2 = high risk.
Key points
- Score ≥ 2 may prompt prophylaxis (apixaban/rivaroxaban/LMWH).
- Weigh against bleeding risk.
- Validated for ambulatory patients starting chemotherapy.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Cancer site | Other (0) |
|---|---|
| Platelets ≥ 350 ×10⁹/L | No |
| Hb < 10 g/dL or using ESA | No |
| WBC > 11 ×10⁹/L | No |
| BMI ≥ 35 kg/m² | No |
→Khorana0
- Risk：Low risk
- Note：Score ≥ 2 identifies higher-risk ambulatory patients in whom thromboprophylaxis (e.g. apixaban/rivaroxaban/LMWH) may be considered.
| Cancer site | Very high risk: stomach, pancreas (2) |
|---|---|
| Platelets ≥ 350 ×10⁹/L | Yes (+1) |
| Hb < 10 g/dL or using ESA | Yes (+1) |
| WBC > 11 ×10⁹/L | Yes (+1) |
| BMI ≥ 35 kg/m² | Yes (+1) |
→Khorana6
- Risk：High risk
- Note：Score ≥ 2 identifies higher-risk ambulatory patients in whom thromboprophylaxis (e.g. apixaban/rivaroxaban/LMWH) may be considered.
Frequently asked questions
- What is Khorana Score (Chemotherapy VTE Risk)?
- Predict chemotherapy-associated VTE risk in ambulatory cancer patients (Khorana score).
- How is Khorana Score (Chemotherapy VTE Risk) calculated? What is the core formula?
- Cancer site (2/1/0) + platelets ≥ 350 (1) + Hb < 10/ESA (1) + WBC > 11 (1) + BMI ≥ 35 (1). ≥ 2 = high risk.
- When is Khorana Score (Chemotherapy VTE Risk) used?
- Decide on outpatient thromboprophylaxis during chemotherapy.
- What are the key clinical points for Khorana Score (Chemotherapy VTE Risk)?
- Score ≥ 2 may prompt prophylaxis (apixaban/rivaroxaban/LMWH). Weigh against bleeding risk. Validated for ambulatory patients starting chemotherapy.
- What are the limits and cautions when using Khorana Score (Chemotherapy VTE Risk)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Khorana Score (Chemotherapy VTE Risk) calculated in practice? Can you show a worked example?
- Inputs: Cancer site Other (0), Platelets ≥ 350 ×10⁹/L No, Hb < 10 g/dL or using ESA No, WBC > 11 ×10⁹/L No, BMI ≥ 35 kg/m² No → Result: Khorana 0（Risk: Low risk, Note: Score ≥ 2 identifies higher-risk ambulatory patients in whom thromboprophylaxis (e.g. apixaban/rivaroxaban/LMWH) may be considered.） Inputs: Cancer site Very high risk: stomach, pancreas (2), Platelets ≥ 350 ×10⁹/L Yes (+1), Hb < 10 g/dL or using ESA Yes (+1), WBC > 11 ×10⁹/L Yes (+1), BMI ≥ 35 kg/m² Yes (+1) → Result: Khorana 6（Risk: High risk, Note: Score ≥ 2 identifies higher-risk ambulatory patients in whom thromboprophylaxis (e.g. apixaban/rivaroxaban/LMWH) may be considered.）